FDA approves cure for sickle cell disease, the first treatment to use gene-editing tool CRISPR
- The U.S. FDA has approved Casgevy, the country's first gene-editing treatment, for sickle cell disease patients aged 12 and older.
- Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR technology to edit genes and treat the disease.
- Analysts raise concerns about the high cost, complexity, and limited availability of the treatment.
Insights by Ground AI
Does this summary seem wrong?
0 Articles
0 Articles
All
Left
Center
Right
Coverage Details
Total News Sources0
Leaning Left35Leaning Right16Center86Last Updated8 months agoBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
62% Center
L 26%
C 62%
12%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage